Try our Advanced Search for more refined results

United Therapeutics Corporation v. Liquidia Technologies, Inc.

  1. April 17, 2024

    United Therapeutics Can't Bar Rival Lung Disease Drug

    Repeating himself for the second time in the last several weeks, a federal judge in Delaware on Wednesday said he won't stop a biochemical startup from launching a drug that would compete directly with one of United Therapeutics' biggest pharmaceutical products.

  2. March 29, 2024

    Del. Judge Clears Liquidia To Sell Lung-Disease Drug

    A Delaware federal judge has ruled that biochemical startup Liquidia can launch its lung disease drug after the Federal Circuit upheld a patent board ruling cutting out the remaining claims in a hypertension patent owned by United Therapeutics that was keeping the drug off the market.

  3. March 12, 2024

    Federal Circuit Won't Reconsider Axing Tyvaso Patent

    The full Federal Circuit on Tuesday declined to review a panel ruling from late last year that sided with a Patent Trial and Appeal Board decision that there was nothing patentable about a way of administering a blockbuster pulmonary hypertension drug.

  4. December 20, 2023

    Fed. Circ. Won't Touch Hypertension Drug Patent Ruling

    The Federal Circuit decided Wednesday to leave untouched a ruling from the patent board that found there was nothing patentable about a purportedly new way of administering a blockbuster pulmonary hypertension drug, potentially shaking up drugmaker United Therapeutics' legal victory against a generic in Delaware federal court. 

  5. September 01, 2022

    Judge Axes 1 Tyvaso Patent, Finds Another Was Infringed

    A Delaware federal judge has invalidated one of United Therapeutics' drug patents for hypertension drug Tyvaso for lack of enablement, but also held that rival Liquidia's planned generic infringes a different Tyvaso patent despite an administrative tribunal's earlier decision to ax it.